Successful treatment of proliferative verrucous leukoplakia with 5% topical imiquimod

Martínez-López, Antonio; Blasco‐Morente, Gonzalo; Pérez-López, Israel; Naranjo-Díaz, M.J.; Aneiros‐Fernández, José; Ruiz‐Villaverde, Ricardo; Sánchez, Jesús Tercedor

doi:10.1111/dth.12413

Cited by 9 publications

(13 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IMQ is a type of non-nucleoside isoimidazole quinoline drug that is mainly used for the topical therapy of skin diseases, such as verruca acuminata, keratosis and HPV-related epithelial dysplasia [ 10 – 12 ]. It was recently found that IMQ is virus- and tumor-resistant and can be used as an activator and B-lymphocyte immune adjuvant [ 13 ] to change the manner of the immune response, induce a specific immune response and improve the body’s protective immunity.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic effect of imiquimod on dextran sulfate sodium-induced ulcerative colitis in mice

et al. 2017

View full text Add to dashboard Cite

BackgroundImiquimod is a Toll-like receptor-7 agonist that regulates immunity and can be used as an immune adjuvant. Ulcerative colitis has a close correlation with immune disorder.AimTo investigate the therapeutic effect of imiquimod on dextran sulfate sodium (DSS)-induced colitis and explore the underlying mechanisms.MethodsC57BL/6J C57 mice received 3% DSS for 7 days to induce ulcerative colitis. Groups of mice were intraperitoneally injected with dexamethasone (DXM, 1.5 mg/kg) or imiquimod (IMQ, 30 mg/kg) at the same time daily. During the experimental period, clinical signs, body weight, stool consistency and visible fecal blood were monitored and recorded daily; colitis was evaluated by disease activity index (DAI) score and by histological score. At the conclusion of the experiment, the level of colonic myeloperoxidase (MPO) activity and the serum levels of the cytokines tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6) and interleukin 10 (IL-10) were measured.ResultsAdministration of 3% DSS for 7 days successfully induced acute colitis associated with diarrhea, bloody mucopurulent stool, body weight decreases, and other changes. Colitis severity was significantly ameliorated in the IMQ treatment groups, as determined by hematoxylin-eosin (HE) staining and histopathological scores. Moreover, IMQ significantly reduced the activity of MPO in colonic tissue and the serum levels of inflammatory cytokines, increased colon length and spleen weight, and effectively inhibited microscopic damage to the colon tissue.ConclusionIMQ had beneficial effects on DSS-induced ulcerative colitis, supporting its further development and clinical application in ulcerative colitis.

show abstract

Section: Introductionmentioning

confidence: 99%

Therapeutic effect of imiquimod on dextran sulfate sodium-induced ulcerative colitis in mice

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The most frequently used application is on alternate days and overnight; three times a week (Martinez-Lopez et al, 2017;Spieth et al, 2006;Yasar et al, 2019), but also two nights a week in combination with 0.1% retinoic acid (Gemigniani et al, 2015), daily use (Mullins et al, 2016), two times a day (Gencoglan et al, 2011) or increasing exposure from 20 min to 2 h every 2 days has also been described (Allam et al, 2008). The treatment weeks ranged between 2 and 16 weeks (Allam et al, 2008;Gemigniani et al, 2015;Gencoglan et al, 2011;Martinez-Lopez et al, 2017;Maschke et al, 2004;Méndez-Flores et al, 2019;Mullins et al, 2016;Rinaggio et al, 2006;Spieth et al, 2006;Wenzel et al, 2003;Yasar et al, 2019). Although in our patient the lesion disappeared at 14 weeks, we maintained the treatment for 16 weeks, as Sirim et al As it was well tolerated and it was the maximum recommended period in the leaflet.…”

Section: Discussionmentioning

confidence: 99%

“…In the oral cavity, imiquimod has also been used for the treatment of different lesions (Allam et al, 2008; Gemigniani et al, 2015; Gencoglan et al, 2011; Martinez‐Lopez et al, 2017; Maschke et al, 2004; Méndez‐Flores et al, 2019; Mullins et al, 2016; Rinaggio et al, 2006; Spieth et al, 2006; Wenzel et al, 2003; Yasar et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

“…to 18 months(Allam et al, 2008;Gemigniani et al, 2015;Gencoglan et al, 2011;Martinez-Lopez et al, 2017;Maschke et al, 2004;Méndez-Flores et al, 2019;Mullins et al, 2016;Rinaggio et al, 2006;Spieth et al, 2006;Wenzel et al, 2003;Yasar et al, 2019).AUTHOR CONTRIBUTIONSPedro Ruiz-Huertas: Created the treatment hypothesis and designed the protocol. Alicia Borrego-Luque: Responsible for clinical procedures and follow-up of patients.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Oral florid papillomatosis: Topical treatment with 5% imiquimod in orabase

Ruiz-Huertas

Borrego-Luque

Toledano-Valero

et al. 2022

Clinical & Exp Dental Res

View full text Add to dashboard Cite

Background Florid oral papillomatosis is characterized by its tendency to local recurrence that requires multiple treatments, leading to important functional sequelae. Methods We present 74‐year‐old woman with oral florid papillomatosis (OFP) who refused a new surgical treatment, and was treated with imiquimod 5% in orabase on alternate days for 16 weeks. Treatment was complemented with application of hyaluronic acid gel. Results There were no side effects to the treatment, nor signs of local recurrence, in the treated area at 2 years of follow‐up. Conclusions After reviewing the literature and according to our knowledge, this is the first published case of oral florid papillomatosis treated topically with imiquimod 5% successfully. Topical treatment with imiquimod 5% in orabase may be a valid alternative for patients with recurrent OFP located in the anterior area of the oral cavity who refuse surgical treatment, although we must closely monitor the patient for the possibility of recurrence or malignant degeneration.

show abstract

“…Timely workup and effective management of leukoplakia is essential to prevent the development of squamous cell carcinoma. Recently, some studies have reported successful therapy with imiquimod 5% cream, which holds promise for a new and effective topical treatment option [1][2][3][4] . Herein, we describe a patient with oral leukoplakia that failed to respond to a 16-week trial of topical imiquimod 5%.…”

Section: To the Editormentioning

confidence: 99%